
    
      OBJECTIVES:

        -  Determine the toxic effects of VNP40101M in patients with relapsed or refractory
           leukemia or poor-risk myelodysplastic syndromes.

        -  Determine the maximum tolerated dose of this drug in these patients.

        -  Determine the pharmacokinetics of this drug in these patients.

        -  Determine the antitumor effects of this drug in these patients.

      OUTLINE: Patients receive VNP40101M IV over 15 minutes once every 4 weeks.

      PROJECTED ACCRUAL: Approximately 40 patients will be accrued for this study.
    
  